• Patients must have pathologically confirmed pancreatic adenocarcinoma with borderline resectable or locally advanced PDAC as defined by NCCN guidelines, with no expected arterial resection-reconstruction.

• Borderline resectable patients only: Completion of inducation chemotherpy within 1-3 weeks of study treatment start. Patients that exceed this window should complete an additional cycle of induction chemotherapy prior to initiation of study treatment, per provider discretion.

• Age ≥ 18 years at time of study entry.

• Provision to sign and date the consent form.

• Stated willingness to comply with all study procedures and be available for the duration of the study.

• Ability to swallow tablets by mouth.

• ECOG performance status ≤2 or KPS ≥60%

• Absolute neutrophil count ≥ 1,000/mcL

• Platelets ≥ 70,000/mcL

⁃ Hemoglobin ≥ 9 g/dL, patients may be transfused to meet this criterion

⁃ Serum albumin ≥ 2.8 g/dL

⁃ Total Bilirubin ≤ 2mg/dL

⁃ AST(SGOT)/ALT(SGPT)/ALP ≤ 3 x institutional upper limit of normal (IULN)

⁃ Measured creatinine clearance (CL) \>40 mL/min or Calculated creatinine CL \>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:

⁃ Males:

⁃ Creatinine CL (mL/min) = Weight (kg) x (140 - Age) / 72 x serum creatinine (mg/dL)

⁃ Females:

⁃ Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 / 72 x serum creatinine (mg/dL)

⁃ INR ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy as long as INR or PTT is within therapeutic range of intended use of anticoagulants

⁃ aPTT ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy as long as INR or PTT is within therapeutic range of intended use of anticoagulants

⁃ Sexually active women of childbearing potential (defined in section 7.1) and men must agree to use at least 1 highly effective method of contraception (defined in section 7.1) from screening and for at least 30 days after administration of the last dose of the study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.